Iktos Market Share Analysis for August 2026

Makya is Iktos’s generative AI SaaS platform, built by chemists for chemists, to design diverse, novel and synthetically accessible molecules that rapidly converge toward drug candidates.

Science and Education > Chemistry

Domainiktos.ai

Year Founded2016

Employees51 - 200

Annual Revenue$2M - $5M

Iktos

Iktos (including company regionals)

iktos.ai

See more website traffic and engagement information

Iktos Revenue up to August 2026 is 2M - 5M

revenue generated by Iktos top domains

Iktos top domains revenue over 3 years

Revenue for Iktos top domains

iktos.ai2M - 5M

See more with Sales Intelligence

Total visits to Iktos's top domains

Understand Iktos market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

iktos.ai9.6K

See more with Sales Intelligence

Avg. visit duration in Iktos's top domains

Analyze Iktos engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

iktos.ai00:00:13

See more with Sales Intelligence

Avg. pageviews on Iktos's top domains

See how Iktos keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

iktos.ai1.82

See more with Sales Intelligence

Iktos top competitors by domain

Top similar sites in August 2026, ranked by their affinity

cas.orgCompany NameCASEmployees1001 - 5000HQUnited States, Ohio, ColumbusAnnual revenue$500M - $1BTotal visits1.2MScience and Education > Chemistry

Top technologies used by Iktos

These are the website technologies, by industry, used by Iktos top domains

Advertising (5)

Google Adsense

Audio Video Media (3)

YouTube

Content Management System (3)

WordPress

Email Services (3)

G Suite

More Technologies

7

See all

News & Signals from Iktos

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsIktos Inc. integrates with Servier Group.The multi-year agreement, with a total potential deal value that could exceed €1 billion, including upfront, research funding, and milestone payments, will combine Iktos' advanced AI-enabled molecular design technologies with Servier's scientific, translational, and clinical development expertise.

NewsPierre Fabre partnered with Iktos Inc. on Jan 1st '26.Pierre Fabre Laboratories and Iktos, a Artificial Intelligence (AI) and Robotics firm specializing in drug discovery, entered an integrated drug discovery collaboration to identify and develop novel small-molecule drug candidates in oncology.

NewsIktos Inc. received financing of $2.61M in grant on Feb 20th '25.PARIS, Feb. 20, 2025 /PRNewswire/ - Iktos, a global leader in AI-driven drug discovery, has secured a prestigious €2.5 million grant from the European Innovation Council (EIC) Accelerator to advance its AI and robotics synthesis automation technology.